ClinicalTrials.gg
CompletedNCT02375971RAINBOWUpdated Nov 14, 2018Results posted

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

A Phase 3 interventional study of Ranibizumab and Laser therapy in Retinopathy of Prematurity, sponsored by Novartis Pharmaceuticals. Completed at 86 sites in 26 countries. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Sex
All
01

Study summary

The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).

Read the detailed description

The study consisted of a screening period (screening and randomization could occur up to 3 days before the administration of the first investigational treatment), followed by a treatment and follow-up period (Day 1 to Day 169).

02

Conditions studied

  • Retinopathy of Prematurity

Keywords

  • intravitreal ranibizumab
  • laser ablation therapy
  • retinopathy of prematurity
  • preterm infants
  • RAINBOW
03

In context

Retinopathy of Prematurity

169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.

This study's enrollment of 224 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.

Browse Retinopathy of Prematurity studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • preterm infants with a birth weight of less than 1500 g
  • bilateral ROP with one of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II, stage 3+ disease, or Aggressive posterior retinopathy of prematurity (AP-ROP)

Exclusion criteria

Exclusion Criteria:

  • ROP disease characteristic in either eye other than that listed above at the time of the first treatment
  • A history of (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes
  • Had received any previous surgical or nonsurgical treatment for ROP (e.g., ablative laser therapy or cryotherapy, vitrectomy)
  • Had been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)
  • Had used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever was longer
  • Had ocular structural abnormalities that were assessed by the Investigator to have had a impact on study assessments
  • Had active ocular infection within 5 days before or on the day of first investigational treatment
  • Had a history of hydrocephalus requiring treatment
  • Had a history of any other neurological conditions that are assessed by the Investigator to have a significant risk of severe impact on visual function
  • Had any other medical conditions or clinically significant comorbidities or personal circumstances that were assessed by the Investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments (e.g., poor , pupil not able to be adequately dilated, unable to comply with the visit schedule)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.2 mg

    1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 0.1 mg

    1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required

    Drug: Ranibizumab

  • Active comparator
    Laser therapy

    Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed

    Procedure: Laser therapy

Interventions

  • Administered as an intravitreal injection

  • ProcedureLaser therapy

    Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24

    To achieve this outcome, patients must fulfill all the following criteria, 1) survival, 2) no intervention with a second modality for ROP, 3) absence of active ROP and 4) absence of unfavorable structural outcome. Retinopathy of prematurity (ROP) is a pathologic process that occurs in the incompletely vascularized, developing retina of low birth-weight preterm neonates.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Requiring Interventions With a Second Modality for ROP at Week 24

    Intervention for ROP in either eye at or before the 24-week assessment visit with a treatment modality other than the modality of the first study treatment. Only descriptive analysis done.

    Time frame: Week 24

  2. Number of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit

    An event was defined as death, treatment switch, or the first occurrence of unfavorable structural outcomes in either eye. Only descriptive analysis done.

    Time frame: Day 1 (after initiation of study treatment) up to study exit (Day 169)

  3. Percentage of Participants Having Recurrent ROP and Receiving Any Post-baseline Intervention at or Before Week 24

    Recurrence of ROP is defined as subjects receiving any post-baseline intervention in either eye at or before 24 weeks (ranibizumab re-treatment or switch to laser in the ranibizumab groups, switch to ranibizumab treatment in the laser group). Zone I consists of a circle, the radius of which extends from the center of the optic disc to twice the distance from the center of the optic disc to the center of the macula. Zone II extends centrifugally from the edge of zone I to the nasal ora serrata. Only descriptive analysis done.

    Time frame: Week 24

  4. Percent of Participants With Ocular Adverse Events by Primary System Organ (SOCs) at Week 24

    Percent of Participants with Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.

    Time frame: Week 24

  5. Mean Change in Ranibizumab Concentration in Pharmacokinetic Serum Samples Over Time at Day 1, Day 15 and Day 29

    Blood samples for the determination of ranibizumab concentrations were collected in the Ranibizumab treatment arms only at the following time points: within 24 hours after the first administration of ranibizumab, at Day 15 and at Day 29. Only descriptive analysis done.

    Time frame: Day 1 (Baseline), Day 15 and Day 29

  6. Mean Change in Vascular Endothelial Growth Factor (VEGF) Levels Over Time at Day 1, Day 15 and Day 29

    Blood samples for the determination of systemic VEGF levels were collected at the following time points: before the first investigational treatment, at Day 15 and at Day 29. Only descriptive analysis done.

    Time frame: Day 1 (Baseline), Day 15 and Day 29

  7. Total Number of Ranibizumab Injections Received at Week 24

    Patients randomized to receive Ranibizumab 0.1 mg or 0.2 mg received a single dose of intravitreal Ranibizumab to each eye on Day 1 (Baseline). Only descriptive analysis done.

    Time frame: Week 24

  8. Percent of Participants With Non-Ocular Adverse Events by Primary System Organ (SOCs) at Week 24

    Percent of Participants with Non-Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.

    Time frame: Week 24

  9. Mean Change From Baseline in Vital Signs (Body Length, Head Circumference and Knee to Heel Length) at Day 85 and Day 169

    Body Length, Head Circumference and Knee to Heel Length were assessed. Only descriptive analysis done.

    Time frame: Baseline, Day 85, Day 169

  10. Mean Change From Baseline in Vital Signs (Weight) at Day 85 and Day 169

    Body weight was measured. Only descriptive analysis done.

    Time frame: Baseline, Day 85, Day 169

  11. Mean Change From Baseline in Vital Signs (Sitting Blood Pressure) at Day 85 and Day 169

    Blood Pressure measurements were not required by the protocol. Instead, the most recent Systolic and Diastolic Blood Pressure expressed in millimeters of mercury (mmHg) measured as part of the routine clinical care were used. Only descriptive analysis done.

    Time frame: Baseline, Day 85, Day 169

07

Results

Posted Jul 31, 2018

Participant flow

This study was conducted in 87 sites: Austria(2), Belgium(2), Croatia(2), Czech Republic(3), Denmark(1), Egypt(1), Estonia(1), France(2), Germany(2), Greece(3), Hungary(2), India(6), Italy(4), Japan(17), Lithuania(1), Malaysia(2), Mexico(1), Poland(2), Romania(3), Russia(5), Saudi Arabia(1), Slovakia(1), Taiwan(2), Turkey(6), UK(3) and USA(12).

Treatment (Day 1 - Baseline)
Participant flow — Treatment (Day 1 - Baseline)
MilestoneRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Started747774
Safety set737669
Vegf set192651
Pk set49460
Completed737669
Not completed115
Withdrew: Subj/guardian decision002
Withdrew: Physician decision111
Withdrew: Lost to follow-up001
Withdrew: Adverse event001
Follow-Up Phase (up to Day 169)
Participant flow — Follow-Up Phase (up to Day 169)
MilestoneRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Started737669
Completed667164
Not completed755
Withdrew: Adverse event100
Withdrew: Subject/guardian decision101
Withdrew: Death444
Withdrew: Withdrawal of consent110

Outcome measures

PrimaryPercentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24

To achieve this outcome, patients must fulfill all the following criteria, 1) survival, 2) no intervention with a second modality for ROP, 3) absence of active ROP and 4) absence of unfavorable structural outcome. Retinopathy of prematurity (ROP) is a pathologic process that occurs in the incompletely vascularized, developing retina of low birth-weight preterm neonates.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24
Percentage of ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 2480.075.066.2
Statistical analysis
  • Ranibizumab 0.2 mg vs Ranibizumab 0.1 mg vs Laser Therapy · Cochran-Mantel-Haenszel · p = 0.0254 · Odds ratio (or): 2.19 · 95% CI 0.9932 to 4.8235
SecondaryPercentage of Participants Requiring Interventions With a Second Modality for ROP at Week 24

Intervention for ROP in either eye at or before the 24-week assessment visit with a treatment modality other than the modality of the first study treatment. Only descriptive analysis done.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring Interventions With a Second Modality for ROP at Week 24
Percentage of participantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Percentage of Participants Requiring Interventions With a Second Modality for ROP at Week 2414.916.924.3
SecondaryNumber of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit

An event was defined as death, treatment switch, or the first occurrence of unfavorable structural outcomes in either eye. Only descriptive analysis done.

Time frame:
Day 1 (after initiation of study treatment) up to study exit (Day 169)
Reported as:
Number · Participants
Number of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit
ParticipantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Number of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit141823
SecondaryPercentage of Participants Having Recurrent ROP and Receiving Any Post-baseline Intervention at or Before Week 24

Recurrence of ROP is defined as subjects receiving any post-baseline intervention in either eye at or before 24 weeks (ranibizumab re-treatment or switch to laser in the ranibizumab groups, switch to ranibizumab treatment in the laser group). Zone I consists of a circle, the radius of which extends from the center of the optic disc to twice the distance from the center of the optic disc to the center of the macula. Zone II extends centrifugally from the edge of zone I to the nasal ora serrata. Only descriptive analysis done.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Having Recurrent ROP and Receiving Any Post-baseline Intervention at or Before Week 24
Percentage of participantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
All participants31.131.218.9
ZONE I35.753.328.6
ZONE II28.317.413.0
SecondaryPercent of Participants With Ocular Adverse Events by Primary System Organ (SOCs) at Week 24

Percent of Participants with Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.

Time frame:
Week 24
Reported as:
Number · Percent of participants
Percent of Participants With Ocular Adverse Events by Primary System Organ (SOCs) at Week 24
Percent of participantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Mild23.332.917.4
Moderate4.16.613.0
Severe2.71.32.9
SecondaryMean Change in Ranibizumab Concentration in Pharmacokinetic Serum Samples Over Time at Day 1, Day 15 and Day 29

Blood samples for the determination of ranibizumab concentrations were collected in the Ranibizumab treatment arms only at the following time points: within 24 hours after the first administration of ranibizumab, at Day 15 and at Day 29. Only descriptive analysis done.

Time frame:
Day 1 (Baseline), Day 15 and Day 29
Reported as:
Mean · picogram/milliliter (pg/mL)
Mean Change in Ranibizumab Concentration in Pharmacokinetic Serum Samples Over Time at Day 1, Day 15 and Day 29
picogram/milliliter (pg/mL)Ranibizumab 0.2 mgRanibizumab 0.1 mg
Day 1 (Baseline)24700.0 ± 52400.0012100.0 ± 25500.0
Day 155830.0 ± 4750.027700.0 ± 144000
Day 291810.0 ± 2990.0732.0 ± 535.0
SecondaryMean Change in Vascular Endothelial Growth Factor (VEGF) Levels Over Time at Day 1, Day 15 and Day 29

Blood samples for the determination of systemic VEGF levels were collected at the following time points: before the first investigational treatment, at Day 15 and at Day 29. Only descriptive analysis done.

Time frame:
Day 1 (Baseline), Day 15 and Day 29
Reported as:
Mean · picogram/milliliter (pg/mL)
Mean Change in Vascular Endothelial Growth Factor (VEGF) Levels Over Time at Day 1, Day 15 and Day 29
picogram/milliliter (pg/mL)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Day 1239.0 ± 226.0230.0 ± 224.0232.0 ± 240.0
Day 1 / no treatment modality switch239.0 ± 226.0239.0 ± 233.0233.0 ± 245.0
Day 15466.0 ± 1500.0118.0 ± 129.0180.0 ± 214.0
Day 15 / no treatment modality switch498.0 ± 1560.0124.0 ± 134.0177.0 ± 224.0
Day 29117.0 ± 84.0176.0 ± 142.0161.0 ± 132.0
Day 29 / no treatment modality switch117.0 ± 84.0139.0 ± 75.3163.0 ± 138.0
SecondaryTotal Number of Ranibizumab Injections Received at Week 24

Patients randomized to receive Ranibizumab 0.1 mg or 0.2 mg received a single dose of intravitreal Ranibizumab to each eye on Day 1 (Baseline). Only descriptive analysis done.

Time frame:
Week 24
Reported as:
Number · Injections
Total Number of Ranibizumab Injections Received at Week 24
InjectionsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Total Number of Ranibizumab Injections Received at Week 24737613
SecondaryPercent of Participants With Non-Ocular Adverse Events by Primary System Organ (SOCs) at Week 24

Percent of Participants with Non-Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.

Time frame:
Week 24
Reported as:
Number · Percent of participants
Percent of Participants With Non-Ocular Adverse Events by Primary System Organ (SOCs) at Week 24
Percent of participantsRanibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Mild37.027.631.9
Moderate24.734.227.5
Severe23.319.717.4
SecondaryMean Change From Baseline in Vital Signs (Body Length, Head Circumference and Knee to Heel Length) at Day 85 and Day 169

Body Length, Head Circumference and Knee to Heel Length were assessed. Only descriptive analysis done.

Time frame:
Baseline, Day 85, Day 169
Reported as:
Mean · centimeter (cm)
Mean Change From Baseline in Vital Signs (Body Length, Head Circumference and Knee to Heel Length) at Day 85 and Day 169
centimeter (cm)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Day 85 / Body Length10.1 ± 2.5911.0 ± 3.3311.1 ± 3.65
Day 169 / Body Length18.7 ± 3.2818.6 ± 3.6619.0 ± 4.50
Day 85 / Head Circumference6.9 ± 1.966.5 ± 2.317.2 ± 2.13
Day 169 / Head Circumference10.4 ± 2.1210.3 ± 2.5610.6 ± 2.61
Day 85 / Knee to Heel Length2.9 ± 1.903.1 ± 1.653.1 ± 2.02
Day 169 / Knee to Heel Length5.4 ± 2.865.1 ± 2.195.3 ± 2.15
SecondaryMean Change From Baseline in Vital Signs (Weight) at Day 85 and Day 169

Body weight was measured. Only descriptive analysis done.

Time frame:
Baseline, Day 85, Day 169
Reported as:
Mean · gram (g)
Mean Change From Baseline in Vital Signs (Weight) at Day 85 and Day 169
gram (g)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Day 85 / Weight2198.9 ± 615.682149.9 ± 754.272182.7 ± 612.70
Day 169 / Weight3794.3 ± 782.483716.7 ± 897.153826.0 ± 882.17
SecondaryMean Change From Baseline in Vital Signs (Sitting Blood Pressure) at Day 85 and Day 169

Blood Pressure measurements were not required by the protocol. Instead, the most recent Systolic and Diastolic Blood Pressure expressed in millimeters of mercury (mmHg) measured as part of the routine clinical care were used. Only descriptive analysis done.

Time frame:
Baseline, Day 85, Day 169
Reported as:
Mean · millimeters of mercury (mmHg)
Mean Change From Baseline in Vital Signs (Sitting Blood Pressure) at Day 85 and Day 169
millimeters of mercury (mmHg)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser Therapy
Day 85 / Sitting Diastolic Blood Pressure8.1 ± 14.667.0 ± 14.259.8 ± 16.95
Day 85 / Sitting Systolic Blood Pressure6.3 ± 15.859.4 ± 15.7315.5 ± 16.85
Day 169 / Sitting Diastolic Blood Pressure11.5 ± 15.6011.8 ± 14.4214.7 ± 17.05
Day 169 / Sitting Systolic Blood Pressure10.2 ± 16.1511.2 ± 13.4517.7 ± 19.35

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit).. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.2 mg4/73 (5.5%)26/73 (35.6%)43/73 (58.9%)
Ranibizumab 0.1 mg4/76 (5.3%)24/76 (31.6%)47/76 (61.8%)
Laser4/69 (5.8%)24/69 (34.8%)37/69 (53.6%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventRanibizumab 0.2 mgRanibizumab 0.1 mgLaser
PneumoniaInfections and infestations4/730/762/69
BronchiolitisInfections and infestations2/734/760/69
Retinopathy of prematurityEye disorders2/731/763/69
Necrotising colitisGastrointestinal disorders0/733/760/69
Respiratory failureRespiratory, thoracic and mediastinal disorders0/733/761/69
VomitingGastrointestinal disorders0/731/762/69
SepsisInfections and infestations0/731/762/69
Perinatal brain damagePregnancy, puerperium and perinatal conditions0/730/762/69
ApnoeaRespiratory, thoracic and mediastinal disorders0/732/762/69
Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders2/732/762/69
Most frequent other events
Showing 10 of 24
Most frequent other events
EventRanibizumab 0.2 mgRanibizumab 0.1 mgLaser
Retinal haemorrhageEye disorders6/7310/767/69
PyrexiaGeneral disorders9/736/764/69
Dermatitis diaperSkin and subcutaneous tissue disorders8/736/764/69
AnaemiaBlood and lymphatic system disorders4/738/765/69
NasopharyngitisInfections and infestations7/735/764/69
PneumoniaInfections and infestations1/731/766/69
Conjunctival haemorrhageEye disorders6/736/762/69
Upper respiratory tract infectionInfections and infestations6/733/761/69
ConjunctivitisInfections and infestations1/736/762/69
Gastrooesophageal reflux diseaseGastrointestinal disorders5/735/764/69

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
Mean25.8 ± 2.2526.5 ± 2.5726.2 ± 2.5926.1 ± 2.48
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
Female414037118
Male333737107
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ranibizumab 0.2 mgRanibizumab 0.1 mgLaser TherapyTotal
American Indian or Alaska Native0000
Asian27222372
Native Hawaiian or Other Pacific Islander0000
Black or African American0437
White434545133
More than one race0000
Unknown or Not Reported46313
08

Study locations

86 sites
  • Novartis Investigative Site
    Loma Linda, California 92354, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Chicago, Illinois 60612, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40208, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02111, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48105, United States
  • Novartis Investigative Site
    Rochester, New York 14642, United States
  • Novartis Investigative Site
    Austin, Texas 78705, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84132, United States
  • Novartis Investigative Site
    Morgantown, West Virginia 26506, United States
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Osijek, 31000, Croatia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Ostrava Poruba, Czech Republic 708 52, Czechia
  • Novartis Investigative Site
    Praha 4 - Podoli, Czech Republic 14700, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Koebenhavn Ø, 2100, Denmark
  • Novartis Investigative Site
    Alexandria, 21131, Egypt
  • Novartis Investigative Site
    Tallinn, 13419, Estonia
  • Novartis Investigative Site
    Amiens Cedex 1, 80054, France
  • Novartis Investigative Site
    Marseille, 13915, France
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Ampelokipi, GR 115 27, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 546 29, Greece
  • Novartis Investigative Site
    Goudi- Athens, 115 27, Greece
  • Novartis Investigative Site
    Budapest, 1125, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380016, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400 008, India
  • Novartis Investigative Site
    Coimbatore, Tamil Nadu 641014, India
  • Novartis Investigative Site
    Madurai, Tamil Nadu 625020, India
  • Novartis Investigative Site
    Vanchiyoor, Thiruvanantapuram 695035, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Firenze, FI 50139, Italy
  • Novartis Investigative Site
    Roma, Lazio 00168, Italy
  • Novartis Investigative Site
    Perugia, PG 06100, Italy
  • Novartis Investigative Site
    Fiumicino, RM 00054, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 453-8511, Japan
  • Novartis Investigative Site
    Nagoya, Aichi 466 8560, Japan
  • Novartis Investigative Site
    Yachiyo-city, Chiba 276-8524, Japan
  • Novartis Investigative Site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Fukuoka-city, Fukuoka 814-0180, Japan
  • Novartis Investigative Site
    Kurume city, Fukuoka 830-0011, Japan
  • Novartis Investigative Site
    Fukushima-city, Fukushima 960-1295, Japan
  • Novartis Investigative Site
    Sapporo-city, Hokkaido, Japan
  • Novartis Investigative Site
    Zentsuji-city, Kagawa 765-8507, Japan
  • Novartis Investigative Site
    Shimajiri-Gun, Okinawa 901-1303, Japan
  • Novartis Investigative Site
    Izumi-city, Osaka 594-1101, Japan
  • Novartis Investigative Site
    Ohtsu-city, Shiga 520-2192, Japan
  • Novartis Investigative Site
    Fuchu-city, Tokyo 183-8561, Japan
  • Novartis Investigative Site
    Ota-ku, Tokyo 143 8541, Japan
  • Novartis Investigative Site
    Setagaya-ku, Tokyo 157-8535, Japan
  • Novartis Investigative Site
    Sumida-ku, Tokyo 130-8575, Japan
  • Novartis Investigative Site
    Toshima-ku, Tokyo 170-8476, Japan
  • Novartis Investigative Site
    Kaunas, LTU LT-50161, Lithuania
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88996, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, Wilayah Persekutuan 50586, Malaysia
  • Novartis Investigative Site
    Querataro, 76090, Mexico
  • Novartis Investigative Site
    Bialystok, 15-274, Poland
  • Novartis Investigative Site
    Wroclaw, 51-124, Poland
  • Novartis Investigative Site
    Brasov, 500025, Romania
  • Novartis Investigative Site
    Bucuresti, 020395, Romania
  • Novartis Investigative Site
    Timisoara, 300041, Romania
  • Novartis Investigative Site
    Cheboksary, 428028, Russian Federation
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Moscow, 127486, Russian Federation
  • Novartis Investigative Site
    Saint-Petersburg, 194100, Russian Federation
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Bratislava, 833 40, Slovakia
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Eskisehir, Meselik 26480, Turkey
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06500, Turkey
  • Novartis Investigative Site
    Istanbul, 34140, Turkey
  • Novartis Investigative Site
    Soguksu / Antalya, 07100, Turkey
  • Novartis Investigative Site
    Zuhuratbaba / Istanbul, 34147, Turkey
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 9DU, United Kingdom
  • Novartis Investigative Site
    Portsmouth, PO6 3LY, United Kingdom
09

References and documents

Publications

  • Fleck BW, Reynolds JD, Zhu Q, Lepore D, Marlow N, Stahl A, Li J, Weisberger A, Fielder AR; RAINBOW Investigator Group. Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial. Ophthalmol Retina. 2022 Jul;6(7):628-637. doi: 10.1016/j.oret.2022.02.006. Epub 2022 Feb 22. PubMed 35202890 ↗
  • Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, Li J, Liew M, Maier R, Zhu Q, Marlow N. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019 Oct 26;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3. Epub 2019 Sep 12. PubMed 31522845 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Dec 2017, 23 months.

Results were first posted in Jul 2018, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2015
First posted
Mar 3, 2015
StartActual
Dec 30, 2015
Primary completionActual
Dec 14, 2017
CompletionActual
Dec 14, 2017
Results first posted
Jul 31, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02375971
Responsible party
Sponsor
First posted
Mar 3, 2015
Start date
Dec 30, 2015
Primary completion
Dec 14, 2017
Completion
Dec 14, 2017
Results posted
Jul 31, 2018
Last update
Nov 14, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion